PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12008177-0 2002 Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Lovastatin 99-109 C-reactive protein Homo sapiens 113-131 15694950-0 2005 Lovastatin compromises C-reactive protein induced endothelial dysfunction including altered expression of cell adhesion molecules and increased monocyte recruitment. Lovastatin 0-10 C-reactive protein Homo sapiens 23-41 15540478-7 2004 AFCAPS/TexCAPS researchers found that lovastatin provded a 14.8% reduction in the median levels of CRP (p < 0.001). Lovastatin 38-48 C-reactive protein Homo sapiens 99-102 11430324-4 2001 METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. Lovastatin 142-152 C-reactive protein Homo sapiens 22-40 11430324-6 2001 Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. Lovastatin 0-10 C-reactive protein Homo sapiens 31-49 11430324-8 2001 However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). Lovastatin 9-19 C-reactive protein Homo sapiens 129-147 19571581-9 2009 Lovastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, by modulating the RhoA activation, significantly reduced leptin-induced CRP production. Lovastatin 0-10 C-reactive protein Homo sapiens 140-143 34607230-8 2021 Besides, in patients, receiving lovastatin the CRP, IL-6, IL-8 levels were significantly decreased from T1 to T3 than to the control group. Lovastatin 32-42 C-reactive protein Homo sapiens 47-50 31628482-3 2020 The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease activity. Lovastatin 90-100 C-reactive protein Homo sapiens 111-114 31628482-4 2020 METHODS: We conducted a randomized double-blind placebo-controlled 12 week trial of lovastatin vs placebo in 64 RA patients with mild clinical disease activity but an elevated CRP. Lovastatin 84-94 C-reactive protein Homo sapiens 176-179 31628482-12 2020 A post hoc analysis of subjects not using biologic therapy demonstrated a significantly greater proportion achieving >=20% reduction in CRP from baseline in the lovastatin group compared with placebo (P-value = 0.007). Lovastatin 161-171 C-reactive protein Homo sapiens 136-139 31628482-16 2020 Lovastatin had a modest effect on CRP in subjects not using biologics, suggesting statins may be anti-inflammatory in selected patients. Lovastatin 0-10 C-reactive protein Homo sapiens 34-37 19395785-0 2009 C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy. Lovastatin 63-73 C-reactive protein Homo sapiens 0-18 19395785-1 2009 INTRODUCTION: We aimed to evaluate the high-sensitivity C-reactive protein (HS-CRP) level changes at the beginning and after withdrawal of lovastatin therapy in patients with diabetic nephropathy. Lovastatin 139-149 C-reactive protein Homo sapiens 56-74 19395785-1 2009 INTRODUCTION: We aimed to evaluate the high-sensitivity C-reactive protein (HS-CRP) level changes at the beginning and after withdrawal of lovastatin therapy in patients with diabetic nephropathy. Lovastatin 139-149 C-reactive protein Homo sapiens 79-82 19395785-8 2009 RESULTS: Serum level of HS-CRP was significantly reduced after 90 days of lovastatin therapy (P < .001). Lovastatin 74-84 C-reactive protein Homo sapiens 27-30 19395785-9 2009 Then, the HS-CRP reached the pretreatment baseline level on the 7th day after lovastatin withdrawal and maintained until the 30th day (P < .001). Lovastatin 78-88 C-reactive protein Homo sapiens 13-16 19395785-12 2009 CONCLUSIONS: Our findings suggest that lovastatin decreases serum CRP level in patients with diabetic nephropathy, and 7 days after lovastatin cessation, CRP level increases again. Lovastatin 39-49 C-reactive protein Homo sapiens 66-69 19395785-12 2009 CONCLUSIONS: Our findings suggest that lovastatin decreases serum CRP level in patients with diabetic nephropathy, and 7 days after lovastatin cessation, CRP level increases again. Lovastatin 39-49 C-reactive protein Homo sapiens 154-157 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Lovastatin 233-243 C-reactive protein Homo sapiens 63-66 16141529-0 2005 Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Lovastatin 0-10 C-reactive protein Homo sapiens 63-81 16141529-6 2005 By using an electrophoretic mobility shift assays (EMSA), we found that CRP (50 microg/ml) increased activation of NF-kappaB and degradation of inhibitory kappa B (IkappaB) in HUVECs, reaching a maximal effect after the incubation with CRP for 1 h. Lovastatin (10(-5) mol/l) diminished NF-kappaB activation induced by CRP. Lovastatin 249-259 C-reactive protein Homo sapiens 72-75